{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:49:30Z","timestamp":1792442970156,"version":"4.5.0"},"reference-count":29,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","award":["ASH Bridge Grant"],"award-info":[{"award-number":["ASH Bridge Grant"]}],"id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001009","name":"Bristol Myers Squibb Foundation","doi-asserted-by":"publisher","award":["Robert A. Winn Diversity in Clinical Trials: Career Development Award (Winn CDA) - Cohort 2"],"award-info":[{"award-number":["Robert A. Winn Diversity in Clinical Trials: Career Development Award (Winn CDA) - Cohort 2"]}],"id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA244899"],"award-info":[{"award-number":["R01CA244899"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA252222"],"award-info":[{"award-number":["R01CA252222"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA196521"],"award-info":[{"award-number":["P30CA196521"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR004421"],"award-info":[{"award-number":["KL2TR004421"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","award":["MMRF 2023 Scholars Grant"],"award-info":[{"award-number":["MMRF 2023 Scholars Grant"]}],"id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>First-degree relatives of patients with multiple myeloma are at increased risk for the disease, but the contribution of pathogenic germline variants (PGV) in hereditary cancer genes to multiple myeloma risk and outcomes is not well characterized. To address this, we analyzed germline exomes in two independent cohorts of 895 and 786 patients with multiple myeloma. PGVs were identified in 8.6% of the Discovery cohort and 11.5% of the Replication cohort, with a notable presence of high- or moderate-penetrance PGVs (associated with autosomal dominant cancer predisposition) in DNA repair genes (3.6% and 4.1%, respectively). PGVs in BRCA1 (OR = 3.9, FDR &amp;lt; 0.01) and BRCA2 (OR = 7.0, FDR &amp;lt; 0.001) were significantly enriched in patients with multiple myeloma when compared with 134,187 healthy controls. Five of the eight BRCA2 PGV carriers exhibited tumor-specific copy number loss in BRCA2, suggesting somatic loss of heterozygosity. PGVs associated with autosomal dominant cancer predisposition were associated with younger age at diagnosis, personal or familial cancer history, and longer progression-free survival after upfront high-dose melphalan and autologous stem-cell transplantation (P &amp;lt; 0.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Our findings suggest up to 10% of patients with multiple myeloma may have an unsuspected cancer predisposition syndrome. Given familial implications and favorable outcomes with high-dose melphalan and autologous stem-cell transplantation in high-penetrance PGV carriers, genetic testing should be considered for young or newly diagnosed patients with a personal or family cancer history.<\/jats:p>\n                    <jats:p>See related commentary by Walker, p. 375<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-23-0208","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T14:37:26Z","timestamp":1726497446000},"page":"428-441","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-5136","authenticated-orcid":false,"given":"Santiago","family":"Thibaud","sequence":"first","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9779-7254","authenticated-orcid":false,"given":"Ryan L.","family":"Subaran","sequence":"additional","affiliation":[{"name":"2Sema4, Stamford, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9309-4752","authenticated-orcid":false,"given":"Scott","family":"Newman","sequence":"additional","affiliation":[{"name":"2Sema4, Stamford, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-0564","authenticated-orcid":false,"given":"Alessandro","family":"Lagana","sequence":"additional","affiliation":[{"name":"3Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"4Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York."},{"name":"5Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2349-1917","authenticated-orcid":false,"given":"David T.","family":"Melnekoff","sequence":"additional","affiliation":[{"name":"3Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7412-477X","authenticated-orcid":false,"given":"Saoirse","family":"Bodnar","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2706-1857","authenticated-orcid":false,"given":"Meghana","family":"Ram","sequence":"additional","affiliation":[{"name":"3Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9460-1899","authenticated-orcid":false,"given":"Zachry","family":"Soens","sequence":"additional","affiliation":[{"name":"2Sema4, Stamford, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5130-9345","authenticated-orcid":false,"given":"William","family":"Genthe","sequence":"additional","affiliation":[{"name":"3Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2874-7777","authenticated-orcid":false,"given":"Tehilla","family":"Brander","sequence":"additional","affiliation":[{"name":"3Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-5978","authenticated-orcid":false,"given":"Tarek H.","family":"Mouhieddine","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5824-197X","authenticated-orcid":false,"given":"Oliver","family":"Van Oekelen","sequence":"additional","affiliation":[{"name":"3Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6781-1700","authenticated-orcid":false,"given":"Jane","family":"Houldsworth","sequence":"additional","affiliation":[{"name":"6Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0274-4292","authenticated-orcid":false,"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8240-5469","authenticated-orcid":false,"given":"Cesar","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9914-5628","authenticated-orcid":false,"given":"Adriana","family":"Rossi","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9353-7680","authenticated-orcid":false,"given":"Larysa","family":"Sanchez","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-7480","authenticated-orcid":false,"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8912-4709","authenticated-orcid":false,"given":"Erin","family":"Moshier","sequence":"additional","affiliation":[{"name":"5Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, New York."},{"name":"7Department of Population Health Science and Policy, Tisch Cancer Institute, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-8469","authenticated-orcid":false,"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2021-6250","authenticated-orcid":false,"given":"Kenan","family":"Onel","sequence":"additional","affiliation":[{"name":"8Clinical Genetics Service, Roswell Park Comprehensive Cancer Center, Buffalo, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"Suppl 12","key":"2026041310190638300_bib1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.22718","article-title":"Multiple myeloma: a review of the epidemiologic literature","volume":"120","author":"Alexander","year":"2007","journal-title":"Int J Cancer"},{"key":"2026041310190638300_bib2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2008-12-191676","article-title":"Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden","volume":"114","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"2026041310190638300_bib3","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.24514","article-title":"Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden","volume":"125","author":"Kristinsson","year":"2009","journal-title":"Int J Cancer"},{"key":"2026041310190638300_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41408-021-00422-6","article-title":"Characterization of rare germline variants in familial multiple myeloma","volume":"11","author":"Catalano","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026041310190638300_bib5","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41375-019-0703-6","article-title":"Genetic predisposition for multiple myeloma","volume":"34","author":"Pertesi","year":"2020","journal-title":"Leukemia"},{"key":"2026041310190638300_bib6","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1200\/JCO.19.02005","article-title":"Prospective feasibility trial of a novel strategy of facilitated cascade genetic testing using telephone counseling","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026041310190638300_bib7","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1200\/JCO.19.02010","article-title":"Cascading after peridiagnostic cancer genetic testing: an alternative to population-based screening","volume":"38","author":"Offit","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026041310190638300_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","article-title":"Pathogenic germline variants in 10,389 adult cancers","volume":"173","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"2026041310190638300_bib9","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.20.03661","article-title":"Therapeutic implications of germline testing in patients with advanced cancers","volume":"39","author":"Stadler","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026041310190638300_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fgene.2015.00157","article-title":"DNA repair mechanisms in cancer development and therapy","volume":"6","author":"Torgovnick","year":"2015","journal-title":"Front Genet"},{"key":"2026041310190638300_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood.2023021384","article-title":"Myeloma and DNA damage","volume":"143","author":"Tonon","year":"2024","journal-title":"Blood"},{"key":"2026041310190638300_bib12","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood-2007-05-089193","article-title":"Dysfunctional homologous recombination mediates genomic instability and progression in myeloma","volume":"113","author":"Shammas","year":"2009","journal-title":"Blood"},{"key":"2026041310190638300_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/jnci\/94.6.461","article-title":"Re: familial multiple myeloma: a family study and review of the literature","volume":"94","author":"Sobol","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2026041310190638300_bib14","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026041310190638300_bib15","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1200\/JCO.2005.10.126","article-title":"Phenotypic heterogeneity in multiple myeloma families","volume":"23","author":"Lynch","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026041310190638300_bib16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/bjh.19271","article-title":"Germline genetic variants in Turkish familial multiple myeloma\/monoclonal gammopathy of undetermined significance cases","volume":"204","author":"Akkus","year":"2024","journal-title":"Br J Haematol"},{"key":"2026041310190638300_bib17","doi-asserted-by":"crossref","first-page":"6644","DOI":"10.1038\/s41467-024-50932-7","article-title":"Deciphering the genetics and mechanisms of predisposition to multiple myeloma","volume":"15","author":"Went","year":"2024","journal-title":"Nat Commun"},{"key":"2026041310190638300_bib18","doi-asserted-by":"crossref","first-page":"168277","DOI":"10.1016\/j.jmb.2023.168277","article-title":"BRCA1\/2 haploinsufficiency: exploring the impact of losing one allele","volume":"436","author":"Minello","year":"2024","journal-title":"J Mol Biol"},{"key":"2026041310190638300_bib19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","article-title":"BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers","volume":"8","author":"Maxwell","year":"2017","journal-title":"Nat Commun"},{"issue":"supplement 1","key":"2026041310190638300_bib20","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1182\/blood-2022-167940","article-title":"Pathogenic germline variants in a prospective multi-center cohort of patients with multiple myeloma","volume":"140","author":"Wiedmeier","year":"2022","journal-title":"Blood"},{"issue":"7 supplement","key":"2026041310190638300_bib21","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1158\/1538-7445.AM2023-5229","article-title":"Abstract 5229: pathogenic germline mutations and risk of multiple myeloma","volume":"83","author":"Conry","year":"2023","journal-title":"Cancer Res"},{"key":"2026041310190638300_bib22","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jamaoncol.2017.1358","article-title":"Lung adenocarcinoma as part of the Li-fraumeni syndrome spectrum: preliminary data of the LIFSCREEN randomized clinical trial","volume":"3","author":"Caron","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026041310190638300_bib23","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/bmt.2009.335","article-title":"Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan","volume":"45","author":"Dumontet","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"2026041310190638300_bib24","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1182\/blood-2004-11-4286","article-title":"The FA\/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells","volume":"106","author":"Chen","year":"2005","journal-title":"Blood"},{"key":"2026041310190638300_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3324\/haematol.2019.240713","article-title":"Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma","volume":"106","author":"Caracciolo","year":"2021","journal-title":"Haematologica"},{"key":"2026041310190638300_bib26","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \u201cBRCAness\u201d sensitizes multiple myeloma cells to PARP inhibitors","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"2026041310190638300_bib27","article-title":"Relating clinical outcomes in multiple myeloma to personal assessment of genetic profile - full text view - ClinicalTrials.gov","author":"ClinicalTrials.gov"},{"key":"2026041310190638300_bib28","unstructured":"SourceForge\n          . SnpEff - browse files at SourceForge.Net [Internet]. [cited 2024 Jan 9]. Available from:https:\/\/sourceforge.net\/projects\/snpeff\/files\/."},{"key":"2026041310190638300_bib29","unstructured":"Releases [Internet]. [cited 2024 Jan 9]. Available from:https:\/\/gnomad.broadinstitute.org\/news\/category\/releases\/."}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0208\/3497951\/bcd-23-0208.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-23-0208\/3508501\/bcd-23-0208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/6\/428\/3509488\/bcd-23-0208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/6\/428\/3509488\/bcd-23-0208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:19:20Z","timestamp":1776089960000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/5\/6\/428\/749229\/Multiple-Myeloma-Risk-and-Outcomes-Are-Associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,9,16]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-23-0208","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.27434306","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434303","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434276","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434288","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434300","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434279","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434294","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434261","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434273","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434285","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434297","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434264","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434270","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.27434282","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.7520348","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]}}}